Jing‐dong Zhou

1.6k total citations
79 papers, 1.1k citations indexed

About

Jing‐dong Zhou is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Jing‐dong Zhou has authored 79 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Hematology, 57 papers in Molecular Biology and 13 papers in Genetics. Recurrent topics in Jing‐dong Zhou's work include Acute Myeloid Leukemia Research (60 papers), Epigenetics and DNA Methylation (31 papers) and Cancer-related gene regulation (16 papers). Jing‐dong Zhou is often cited by papers focused on Acute Myeloid Leukemia Research (60 papers), Epigenetics and DNA Methylation (31 papers) and Cancer-related gene regulation (16 papers). Jing‐dong Zhou collaborates with scholars based in China, United States and Canada. Jing‐dong Zhou's co-authors include Jiang Lin, Ting‐juan Zhang, Ji‐chun Ma, Xiang‐mei Wen, Jun Qian, Zi‐jun Xu, Zhaoqun Deng, Hong Guo, Dong‐ming Yao and Yangjing Zhao and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biochemical and Biophysical Research Communications and Frontiers in Immunology.

In The Last Decade

Jing‐dong Zhou

75 papers receiving 1.1k citations

Peers

Jing‐dong Zhou

HEMAT

ONCOL

GENET

Nabilah Khan United States

Seshagiri Duvvuri United States

Laura Cicconi Italy

William Tse United States

W-L Zhao China

Irene Gañán‐Gómez United States

M. T. Smith United Kingdom

S. M. LUDEMAN United States

Manman Deng China

Takuro Nishikawa Japan

Nabilah Khan United States

Jing‐dong Zhou

892 ×1.0

703 ×1.4

HEMAT

458 ×1.2

168 ×1.4

ONCOL

110 ×1.2

GENET

Citations per year, relative to Jing‐dong Zhou Jing‐dong Zhou (= 1×) peers Nabilah Khan

Countries citing papers authored by Jing‐dong Zhou

Since Specialization

Citations

This map shows the geographic impact of Jing‐dong Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jing‐dong Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jing‐dong Zhou more than expected).

Fields of papers citing papers by Jing‐dong Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jing‐dong Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jing‐dong Zhou. The network helps show where Jing‐dong Zhou may publish in the future.

Co-authorship network of co-authors of Jing‐dong Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Jing‐dong Zhou. A scholar is included among the top collaborators of Jing‐dong Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jing‐dong Zhou. Jing‐dong Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhao, Yangjing, Jiaxin Xu, Yue You, et al.. (2025). ID1 in hematopoiesis and hematologic disorders: novel potentials of a classic differentiation regulator. Cellular & Molecular Biology Letters. 30(1). 124–124.

Gong, Xiaoqing, Qixian Wu, Jing‐dong Zhou, et al.. (2024). Identification and validation of cuproptosis and disulfidptosis related genes in colorectal cancer. Cellular Signalling. 119. 111185–111185. 6 indexed citations

Zhao, Yangjing, Weili Cai, Hua Ye, Xiaochen Yang, & Jing‐dong Zhou. (2022). The Biological and Clinical Consequences of RNA Splicing Factor U2AF1 Mutation in Myeloid Malignancies. Cancers. 14(18). 4406–4406. 16 indexed citations

Zhao, Yangjing, Hui Wang, Jing‐dong Zhou, & Qixiang Shao. (2022). Glutathione Peroxidase GPX1 and Its Dichotomous Roles in Cancer. Cancers. 14(10). 2560–2560. 68 indexed citations

Gu, Yu, Zi‐jun Xu, Jing‐dong Zhou, et al.. (2021). Abnormal expression and methylation of PRR34‐AS1 are associated with adverse outcomes in acute myeloid leukemia. Cancer Medicine. 10(15). 5283–5296. 5 indexed citations

Zhang, Ting‐juan, Zi‐jun Xu, Yu Gu, et al.. (2021). Identification and validation of obesity-related gene LEP methylation as a prognostic indicator in patients with acute myeloid leukemia. Clinical Epigenetics. 13(1). 16–16. 14 indexed citations

Zhang, Ting‐juan, et al.. (2021). Distinct associations of NEDD4L expression with genetic abnormalities and prognosis in acute myeloid leukemia. Cancer Cell International. 21(1). 615–615. 4 indexed citations

Zhang, Ting‐juan, Zi‐jun Xu, Yu Gu, et al.. (2020). Identification and validation of prognosis‐related DLX5 methylation as an epigenetic driver in myeloid neoplasms. SHILAP Revista de lepidopterología. 10(2). e29–e29. 28 indexed citations

Zhang, Ting‐juan, et al.. (2020). Distinct association of RUNX family expression with genetic alterations and clinical outcome in acute myeloid leukemia. Cancer Biomarkers. 29(3). 387–397. 2 indexed citations

10.

Zhang, Ting‐juan, Xiang‐mei Wen, Jing‐dong Zhou, et al.. (2019). SOX30 methylation correlates with disease progression in patients with chronic myeloid leukemia. OncoTargets and Therapy. Volume 12. 4789–4794. 9 indexed citations

11.

Zhang, Ting‐juan, Zi‐jun Xu, Yu Gu, et al.. (2019). EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia. Journal of Cellular and Molecular Medicine. 24(2). 1640–1649. 10 indexed citations

12.

Li, Xixi, Jing‐dong Zhou, Xiang‐mei Wen, et al.. (2019). Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia. OncoTargets and Therapy. Volume 12. 3295–3304. 32 indexed citations

13.

Tang, Li‐Juan, Jing‐dong Zhou, Zi‐jun Xu, et al.. (2019). DOK6 promoter methylation serves as a potential biomarker affecting prognosis in de novo acute myeloid leukemia. Cancer Medicine. 8(14). 6393–6402. 3 indexed citations

14.

Yang, Lan, Jing‐dong Zhou, Ting‐juan Zhang, et al.. (2018). Overexpression of lncRNA PANDAR predicts adverse prognosis in acute myeloid leukemia. Cancer Management and Research. Volume 10. 4999–5007. 30 indexed citations

15.

Zhang, Ting‐juan, Jing‐dong Zhou, Dongqin Yang, et al.. (2017). TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia. Journal of Cellular Physiology. 233(8). 5838–5846. 25 indexed citations

16.

Zhou, Jing‐dong, Jiang Lin, Ting‐juan Zhang, et al.. (2017). Hypomethylation‐mediated H19 overexpression increases the risk of disease evolution through the association with BCR‐ABL transcript in chronic myeloid leukemia. Journal of Cellular Physiology. 233(3). 2444–2450. 24 indexed citations

17.

Xu, Zi‐jun, Jing‐dong Zhou, Xi-xi Li, et al.. (2017). Methylation‐associated DOK1 and DOK2 down‐regulation: Potential biomarkers for predicting adverse prognosis in acute myeloid leukemia. Journal of Cellular Physiology. 233(9). 6604–6614. 15 indexed citations

18.

Zhang, Ting‐juan, Jing‐dong Zhou, Xixi Li, et al.. (2017). Overexpression of miR‐216b: Prognostic and predictive value in acute myeloid leukemia. Journal of Cellular Physiology. 233(4). 3274–3281. 15 indexed citations

19.

Zhou, Jing‐dong, Ting‐juan Zhang, Xi-xi Li, et al.. (2017). Methylation‐independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia. Journal of Cellular Physiology. 233(6). 4707–4714. 6 indexed citations

20.

Zhou, Jing‐dong. (2011). Investigation on Personality and Mental Health Among the Migrant Workers in Guangzhou City,2010. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact